Racecadotril
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Racecadotril: From Acute Diarrhea to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Racecadotril is an enkephalinase (neutral endopeptidase) inhibitor whose established clinical use is the treatment of acute diarrhea. The TxGNN model predicts a possible effect on Polyclonal Hyperviscosity Syndrome, but this prediction is currently supported by 0 clinical trials and 0 publications, and the underlying mechanistic rationale is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute diarrhea (established pharmacological use; no formal Danish registration record available in this data pack) |
| Predicted New Indication | Polyclonal Hyperviscosity Syndrome |
| TxGNN Prediction Score | 97.72% |
| Evidence Level | L5 |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data was not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, Racecadotril is an enkephalinase (NEP) inhibitor that reduces intestinal hypersecretion, and its efficacy in acute diarrhea is well established and widely used clinically.
Polyclonal hyperviscosity syndrome is driven by excess circulating immunoglobulins (e.g., from polyclonal plasma cell/B-cell activity) increasing blood viscosity — a pathophysiology unrelated to intestinal enkephalinase activity. There is no known biological pathway connecting NEP inhibition to plasma viscosity regulation.
Given the absence of mechanistic overlap and the complete lack of supporting clinical or literature evidence, this prediction most likely reflects a knowledge-graph embedding similarity artifact rather than a genuine pharmacological signal. The same caveat applies to the other top-ranked predictions in this evidence pack (hyperamylasemia, congenital analbuminemia, blood group incompatibility, premalignant hematological system disease), none of which have a plausible mechanistic link to Racecadotril’s known action.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
No marketing authorisation is currently registered for Racecadotril in Denmark (market status: Not Marketed; 0 authorisations on file).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or literature evidence supporting Racecadotril’s use in Polyclonal Hyperviscosity Syndrome, and the mechanistic rationale is implausible given its known enkephalinase-inhibitor pharmacology. A blocking data gap (missing local product label / warnings) also prevents any safety pre-assessment.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- Local product label / SmPC warnings and contraindications (currently blocking)
- Any preclinical or mechanistic studies linking NEP inhibition to plasma viscosity or immunoglobulin regulation, if they exist
- Re-evaluation if future clinical or literature evidence emerges for this indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.